FARS2

Across TCGA pan-cancer cohorts, FARS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FARS2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FARS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FARS2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where FARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.985	0.237	.017	15	view →
UCEC	DFS	Tertile	All	0.740	0.928	.025	6	view →
PDAC	DFS	Median	III,IV	0.933	0.440	.007	6	view →
LUAD	OS	Tertile	II,III,IV	0.822	0.334	.017	4	view →
HNSC	OS	Median	IV	0.836	0.611	.010	4	view →
GBM	OS	Median	All	0.910	0.627	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FARS2–CCRCC (OS)

Open the CCRCC breakdown →